News Archive
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.
Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.
Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. Now, researchers at the La Jolla Institute for Allergy and Immunology demonstrate that TET proteins collectively constitute a major class of tumor suppressors and are required to maintain genome instability.
The combination of cell and gene therapy is rapidly raising clinical interest, although their combination has been under investigation for several decades. This is mainly due to the availability and feasibility of clinically relevant gene delivery options. This review focuses on cell therapies for heart failure and their use combined with cardiac surgery as well as with gene therapy.
› Verified 4 days ago